Home Featured Page 171

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Awakn Life Sciences Announces Closing of Private Placement

PT303 – Adam Bramlage – Cannabis, Microdosing, and Our Evolutionary Connection...

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

PT302 – Dr. Adele Lafrance – Vital Psychedelic Conversations

How Can We Apply Harm Reduction to HPPD?

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London...

Green Market Report – Are Psychedelics Leaving Minorities Behind?

MINDCURE Provides Update on Strategic Review

Nova Mentis Announces Closing of Non-Brokered Financing

Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

1...170171172...296 Page 171 of 296

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Awakn Life Sciences Announces Closing of Private Placement

PT303 – Adam Bramlage – Cannabis, Microdosing, and Our Evolutionary Connection...

Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?

PT302 – Dr. Adele Lafrance – Vital Psychedelic Conversations

How Can We Apply Harm Reduction to HPPD?

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London...

Green Market Report – Are Psychedelics Leaving Minorities Behind?

MINDCURE Provides Update on Strategic Review

Nova Mentis Announces Closing of Non-Brokered Financing

Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY